Transarterial Radioembolization for Hepatocellular Carcinoma and Hepatic Metastases: Clinical Aspects and Dosimetry Models

Overview

Journal Semin Radiat Oncol

Specialties Oncology
Radiology

Date 2019 Nov 16

PMID 31727302

Citations 16

Authors

Justin K Mikell

Yuni K Dewaraja

Dawn Owen

Affiliations

Soon will be listed here.

Abstract

Transarterial radioembolization (TARE) with Yttrium-90 (Y) microspheres is a liver-directed therapy for primary and metastatic disease. This manuscript provides a review of the clinical literature on TARE indications and efficacy with overviews of patient-selection and toxicity. Current dosimetry models used in practice are safe, relatively simple, and easy for clinicians to use. Planning currently relies on the imperfect surrogate, Tc macroaggregated albumin. Post-therapy quantitative imaging (Y SPECT/CT or Y PET/CT) of microspheres can be used to calculate the macroscopic in vivo absorbed dose distribution. Similar to the evolution of other brachytherapy dose calculations, TARE is moving toward more patient-specific dosimetry that includes calculating and reporting nonuniform dose distributions throughout tumors and normal uninvolved liver.

Citing Articles

Preparation of iodine-131 labeled Polyvinyl alcohol-collagen microspheres for radioembolization therapy of liver tumors.

Li Y, Cai H, Xing Y, Pang F, Li L Sci Rep. 2025; 15(1):8830.

PMID: 40087534 DOI: 10.1038/s41598-025-94162-3.

Conventional transarterial chemoembolization followed by irreversible electroporation for hepatocellular carcinoma.

Zhao M, Li F, Tian C, Cai D, Wang C BMC Cancer. 2025; 25(1):313.

PMID: 39984913 PMC: 11843783. DOI: 10.1186/s12885-025-13570-w.

The Objective Response and Disease Control Rates in Patients with Liver Metastastic Breast Cancer Receiving Transarterial Radioembolization: A Meta-Analysis.

Quartuccio N, Militano V, Pappalardo M, Filippi L, Bagni O, Moreci A Curr Oncol. 2024; 31(11):6879-6890.

PMID: 39590139 PMC: 11592458. DOI: 10.3390/curroncol31110508.

Clinical Results of Holmium-166 Radioembolization with Personalized Dosimetry for the Treatment of Hepatocellular Carcinoma.

Kuhnel C, Kohler A, Brachwitz T, Seifert P, Guhne F, Aschenbach R J Pers Med. 2024; 14(7).

PMID: 39064001 PMC: 11278198. DOI: 10.3390/jpm14070747.

[Modern TARE 2023 - from palliative care to a curative treatment alternative].

Gebauer B, Collettini F, Pfob C, Lapa C Nuklearmedizin. 2024; 63(6):328-336.

PMID: 39013456 PMC: 11614522. DOI: 10.1055/a-2353-5819.

References

Mosconi C, Cucchetti A, Pettinato C, Golfieri R, Cappelli A . Validation of response to yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. J Hepatol. 2018; 69(1):259-260. DOI: 10.1016/j.jhep.2018.02.027. View

Teo J, Allen Jr J, Ng D, Choo S, Tai D, Chang J . A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90. HPB (Oxford). 2016; 18(1):7-12. PMC: 4750235. DOI: 10.1016/j.hpb.2015.07.002. View

Bastiaannet R, Viergever M, W A M de Jong H . Impact of respiratory motion and acquisition settings on SPECT liver dosimetry for radioembolization. Med Phys. 2017; 44(10):5270-5279. DOI: 10.1002/mp.12483. View

Knesaurek K, Machac J, Muzinic M, DaCosta M, Zhang Z, Heiba S . Quantitative comparison of yttrium-90 (90Y)-microspheres and technetium-99m (99mTc)-macroaggregated albumin SPECT images for planning 90Y therapy of liver cancer. Technol Cancer Res Treat. 2010; 9(3):253-62. DOI: 10.1177/153303461000900304. View

Gnesin S, Canetti L, Adib S, Cherbuin N, Silva Monteiro M, Bize P . Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison. J Nucl Med. 2016; 57(11):1672-1678. DOI: 10.2967/jnumed.116.173104. View

Pardo F, Sangro B, Lee R, Manas D, Jeyarajah R, Donckier V . The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres. Ann Surg Oncol. 2017; 24(9):2465-2473. DOI: 10.1245/s10434-017-5950-z. View

Wahl D, Stenmark M, Tao Y, Pollom E, Caoili E, Lawrence T . Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. J Clin Oncol. 2015; 34(5):452-9. PMC: 4872011. DOI: 10.1200/JCO.2015.61.4925. View

van Lienden K, van den Esschert J, De Graaf W, Bipat S, Lameris J, van Gulik T . Portal vein embolization before liver resection: a systematic review. Cardiovasc Intervent Radiol. 2012; 36(1):25-34. PMC: 3549243. DOI: 10.1007/s00270-012-0440-y. View

Weiner A, Olsen J, Ma D, Dyk P, DeWees T, Myerson R . Stereotactic body radiotherapy for primary hepatic malignancies - Report of a phase I/II institutional study. Radiother Oncol. 2016; 121(1):79-85. PMC: 5543719. DOI: 10.1016/j.radonc.2016.07.020. View

10.

Campbell A, Bailey I, Burton M . Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol. 2000; 45(4):1023-33. DOI: 10.1088/0031-9155/45/4/316. View

11.

de la Torre M, Buades-Mateu J, de la Rosa P, Lue A, Bustamante F, Serrano M . A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib. Liver Int. 2016; 36(8):1206-12. DOI: 10.1111/liv.13098. View

12.

Dabadie P, Hesse M, Jamar F, Lhommel R, Walrand S . Y TOF-PET based EUD reunifies patient survival prediction in resin and glass microspheres radioembolization of HCC tumours. Phys Med Biol. 2018; 63(24):245010. DOI: 10.1088/1361-6560/aaf205. View

13.

Dezarn W, Cessna J, DeWerd L, Feng W, Gates V, Halama J . Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys. 2011; 38(8):4824-45. DOI: 10.1118/1.3608909. View

14.

Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F . EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011; 38(7):1393-406. DOI: 10.1007/s00259-011-1812-2. View

15.

Gordon A, Gabr A, Riaz A, Uddin O, Abouchaleh N, Ali R . Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2018; 41(10):1557-1565. PMC: 6128743. DOI: 10.1007/s00270-018-2008-y. View

16.

Tafti B, Padia S . Dosimetry of Y-90 Microspheres Utilizing Tc-99m SPECT and Y-90 PET. Semin Nucl Med. 2019; 49(3):211-217. DOI: 10.1053/j.semnuclmed.2019.01.005. View

17.

Lee D, Seong J . Radiotherapeutic options for hepatocellular carcinoma with portal vein tumor thrombosis. Liver Cancer. 2014; 3(1):18-30. PMC: 3995383. DOI: 10.1159/000343855. View

18.

Carlier T, Willowson K, Fourkal E, Bailey D, Doss M, Conti M . (90)Y -PET imaging: Exploring limitations and accuracy under conditions of low counts and high random fraction. Med Phys. 2015; 42(7):4295-309. DOI: 10.1118/1.4922685. View

19.

Braat M, Samim M, van den Bosch M, Lam M . The role of Y-radioembolization in downstaging primary and secondary hepatic malignancies: a systematic review. Clin Transl Imaging. 2016; 4:283-295. PMC: 4960274. DOI: 10.1007/s40336-016-0172-0. View

20.

Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca A, Pageaux G . Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017; 18(12):1624-1636. DOI: 10.1016/S1470-2045(17)30683-6. View